Clinical profile of patients using normal, high and very high insulin doses in type 2 diabetes

2014 ◽  
Vol 8 (2) ◽  
pp. 72-74 ◽  
Author(s):  
K.V.S. Hari Kumar ◽  
A.K. Gupta ◽  
Amit Kumar
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Profile ◽  
High Insulin ◽  
Very High

Insulin dose-response studies in severely insulin-resistant type 2 diabetes-evidence for effectiveness of very high insulin doses

2011 ◽  
Vol 13 (6) ◽  
pp. 511-516 ◽  
Author(s):  
U. Kampmann ◽  
P. Hoeyem ◽  
A. Mengel ◽  
O. Schmitz ◽  
J. Rungby ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dose Response ◽  
Insulin Dose ◽  
Insulin Resistant ◽  
High Insulin ◽  
Very High

Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements

2020 ◽  
Vol 17 (1) ◽  
pp. 26-29
Author(s):  
Nasser Mikhail
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Trials ◽  
Regular Insulin ◽  
Injection Pain ◽  
Regular Human Insulin ◽  
Efficacy And Safety ◽  
Insulin Requirements ◽  
High Insulin

Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin. Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020. Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors. Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.

scholarly journals Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Basilio Pintaudi ◽  
Alessia Scatena ◽  
Gabriella Piscitelli ◽  
Vera Frison ◽  
Salvatore Corrao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Quality Of Care ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Cardiovascular Risk Factors ◽  
High Cardiovascular Risk ◽  
Very High

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, intensity/appropriateness of pharmacological treatment for diabetes and cardiovascular risk factors, presence of other complications and overall quality of care were evaluated. Results Overall, 473,740 subjects with type 2 diabetes (78.5% at very high cardiovascular risk, 20.9% at high risk and 0.6% at moderate risk) were evaluated. Among people with T2D at very high risk: 26.4% had retinopathy, 39.5% had albuminuria, 18.7% had a previous major cardiovascular event, 39.0% had organ damage, 89.1% had three or more risk factors. The use of DPP4-i markedly increased as cardiovascular risk increased. The prescription of secretagogues also increased and that of GLP1-RAs tended to increase. The use of SGLT2-i was still limited, and only slightly higher in subjects with very high cardiovascular risk. The overall quality of care, as summarized by the Q score, tended to be lower as the level of cardiovascular risk increased. Conclusions A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction. Several actions are necessary to improve the quality of care.

scholarly journals Clinical profile of asymptomatic bacteriuria in type 2 diabetes mellitus: An Eastern India perspective

2019 ◽  
Vol 23 (3) ◽  
pp. 293
Author(s):  
Indira Maisnam ◽  
Mainak Banerjee ◽  
Manidipa Majumdar ◽  
PrabirK Kundu ◽  
ApurbaK Mukherjee
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Asymptomatic Bacteriuria ◽  
Clinical Profile ◽  
Eastern India

Impact of ethnicity and obesity on insulin resistance in two ethnic groups at very high risk of type 2 diabetes

2017 ◽  
Vol 43 (3) ◽  
pp. 292-294 ◽  
Author(s):  
S. Hassoun ◽  
M. Al-Atrash ◽  
M. Alkasim ◽  
Z. Dabbous ◽  
O. Mujahed ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
High Risk ◽  
Ethnic Groups ◽  
Very High

Comorbidities and Diabetes Type 2

2021 ◽  
pp. 46-61
Author(s):  
Chinedu I. Ossai ◽  
Nilmini Wickramasinghe ◽  
Steven Goldberg
Keyword(s):  
Type 2 Diabetes ◽  
High Risk ◽  
Logit Model ◽  
Diabetes Type 2 ◽  
Cost Effective ◽  
Diabetes Type ◽  
High Quality ◽  
Chi Square ◽  
Very High

The prevalence of diabetes type 2 among the population and the increasing rate of new diagnoses as well as other co-morbidities make it imperative that we develop a richer understanding of type 2 diabetes. An Australian survey of diabetes type 2 people for different co-morbidities was carried out to obtain information about the possible connections of the co-morbidities with type 2 diabetes. The analysis is done with the logit model and Pearson's chi-square and the results indicate that gender, age of the patients, and the duration of the diabetes type 2 diagnosis play a significant role in the exposure of individuals to different comorbidities. The influence of the duration of diagnosis and age of the patients is limited in comparison to the gender, which has females at a very high risk of developing the studied co-morbidities compared to males. The findings can improve diabetes type 2 management to boost high quality, proactive, and cost-effective caregiving for the patients.

Sign in / Sign up

Export Citation Format

Share Document